# Clinical Trials İlgili Makaleler

Coinbase Founder Is Now Researching Immortality

Coinbase Founder Invests in the "Fountain of Youth": NewLimit's $435M Funding to Reverse Aging Brian Armstrong, co-founder and CEO of Coinbase, is now targeting a new frontier: human longevity. His biotech startup, NewLimit, has just raised $435 million in a Series C round led by Peter Thiel’s Founders Fund, valuing the company at $3.1 billion. The funding will advance its mission to develop therapies that slow or even reverse cellular aging, with its first drug targeting alcohol-related liver disease set to enter clinical trials next year. Founded in 2021 by Armstrong, former GV partner Blake Byers, and stem cell biologist Jacob Kimmel, NewLimit builds on Nobel Prize-winning research by Shinya Yamanaka, who discovered that adult cells can be reprogrammed to a younger state. NewLimit’s approach focuses on identifying specific gene combinations to reset the "epigenetic age" of cells, aiming first to treat diseases viewed as accelerated aging before broadening its applications. The company joins a growing field of longevity startups backed by tech billionaires, including Sam Altman’s investment in Retro Biosciences and Jeff Bezos’s support for Altos Labs. For these ultra-wealthy backers, conquering aging represents the ultimate investment—extending the one resource even immense wealth cannot buy: time.

Odaily星球日报16 saat önce